[go: up one dir, main page]

GT200500028A - Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos. - Google Patents

Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.

Info

Publication number
GT200500028A
GT200500028A GT200500028A GT200500028A GT200500028A GT 200500028 A GT200500028 A GT 200500028A GT 200500028 A GT200500028 A GT 200500028A GT 200500028 A GT200500028 A GT 200500028A GT 200500028 A GT200500028 A GT 200500028A
Authority
GT
Guatemala
Prior art keywords
oxadiazolones
pharmaceutical products
procedures
preparation
useful
Prior art date
Application number
GT200500028A
Other languages
English (en)
Inventor
Jochen Goerlitzer
Stefanie Keil
Maike Glien
Wolfgang Wendler
Daniel G Mcgarry
Jean Merrill
Karen Chandross
Patrick Bernadelli
Baptiste Ronan
Corinne Terrier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500028A publication Critical patent/GT200500028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A OXADIAZOLONAS DE FORMULA I ASI COMO A SUS SALES FISIOLOGICAMENTE ACEPTABLES, A SU PROCESO DE PREPARACION Y A SU USO COMO PRODUCTOS FARMACEUTICOS, ESTAS OXIDIAZOLONAS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE DESORDENES EN EL CUAL LA RESISTENCIA A LA INSULINA ES IMPORTANTE, TAMBIEN ES UTIL PARA EL TRATAMIENTO DE DESORDENES NEURODEGENERATIVOS ASI COMO ENFERMEDADES NEUROLOGICAS QUE CON LLEVAN PROCESOS NEUROINFLAMATORIOS O NEUROPATIAS PERIFERICAS.
GT200500028A 2004-04-01 2005-02-17 Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos. GT200500028A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (en) 2004-04-01 2004-04-01 Oxadiazolones, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
GT200500028A true GT200500028A (es) 2006-06-09

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500028A GT200500028A (es) 2004-04-01 2005-02-17 Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.

Country Status (37)

Country Link
US (3) US20070179191A1 (es)
EP (3) EP1586573B1 (es)
JP (1) JP2007530612A (es)
KR (1) KR20060135857A (es)
CN (1) CN100582104C (es)
AR (1) AR050576A1 (es)
AT (1) ATE435225T1 (es)
AU (1) AU2005231916A1 (es)
BR (1) BRPI0509517A (es)
CA (1) CA2561627A1 (es)
CR (1) CR8572A (es)
CY (1) CY1109370T1 (es)
DE (2) DE602004004631D1 (es)
DK (1) DK1740583T3 (es)
DO (1) DOP2005000051A (es)
EC (1) ECSP066892A (es)
ES (1) ES2329484T3 (es)
GT (1) GT200500028A (es)
HR (1) HRP20090493T1 (es)
IL (1) IL178056A0 (es)
MA (1) MA28495B1 (es)
MY (1) MY142431A (es)
NO (1) NO20064981L (es)
PA (1) PA8628701A1 (es)
PE (1) PE20060323A1 (es)
PL (1) PL1740583T3 (es)
PT (1) PT1740583E (es)
RS (1) RS51186B (es)
RU (1) RU2374243C2 (es)
SI (1) SI1740583T1 (es)
SV (1) SV2006002071A (es)
TN (1) TNSN06317A1 (es)
TW (1) TW200602342A (es)
UA (1) UA84203C2 (es)
UY (1) UY28837A1 (es)
WO (1) WO2005097786A1 (es)
ZA (1) ZA200606870B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
JP5183479B2 (ja) * 2005-09-29 2013-04-17 サノフイ フェニル基を有するフェニル−［１，２，４］−オキサジアゾール−５−オン誘導体、その製造方法、及び医薬品としてのその使用
NZ566876A (en) 2005-09-29 2010-05-28 Sanofi Aventis Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
KR101922515B1 (ko) 2006-09-08 2019-02-20 로드아일랜드하스피틀 알코올 유발성 간 질환의 치료, 예방 및 역행
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2010000353A1 (en) * 2008-06-09 2010-01-07 Sanofi-Aventis Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
WO2009149819A1 (en) * 2008-06-09 2009-12-17 Sanofi-Aventis Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
JP2011523664A (ja) 2008-06-09 2011-08-18 サノフィ−アベンティス オキサジアゾロン頭部基を有する、環付加された（ａｎｎｅｌａｔｅｄ）Ｎ−複素環式スルホンアミド、それらの製造方法および医薬としてのそれらの使用
CN102202672A (zh) 2008-10-10 2011-09-28 达拉生物科学公司 使用穗霉素衍生物治疗或预防疼痛的方法
LT3135672T (lt) * 2008-10-10 2020-05-25 Vm Discovery, Inc. Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
JP5546543B2 (ja) * 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
JP5546542B2 (ja) * 2009-08-05 2014-07-09 第一三共株式会社 アミド誘導体
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives
US20220387393A1 (en) * 2019-11-06 2022-12-08 Board Of Regents, The University Of Texas System Methods for the treatment of dysmyelinating/demyelinating diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) * 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW222626B (es) * 1991-07-22 1994-04-21 Pfizer
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
IL148148A0 (en) 1999-09-01 2002-09-12 Aventis Pharma Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
WO2001040171A1 (en) 1999-12-03 2001-06-07 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
IL151368A0 (en) 2000-03-31 2003-04-10 Probiodrug Ag Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
EP1277745A4 (en) 2000-04-25 2004-09-15 Kyorin Seiyaku Kk NEW STABLE CRYSTALS OF THIAZOLIDINDION DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
US6861444B2 (en) 2000-04-28 2005-03-01 Asahi Kasei Pharma Corporation Bicyclic compounds
MXPA02010452A (es) 2000-05-11 2003-06-06 Bristol Myers Squibb Co Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento.
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
MXPA02011458A (es) 2000-06-09 2003-04-25 Aventis Pharma Gmbh Derivados de acilfenilurea, metodos para su produccion y uso de los mismos como farmacos.
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU1609702A (en) 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
EP1368011A1 (en) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Method for treating ppar gamma mediated diseases
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
EE05418B1 (et) 2001-08-31 2011-06-15 Aventis Pharma Deutschland Gmbh Diarltskloalklderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
AU2002347985A1 (en) * 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004094394A1 (en) 2003-04-01 2004-11-04 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
US7217727B2 (en) 2003-04-01 2007-05-15 Eli Lilly And Company Phospholipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
JP5183479B2 (ja) * 2005-09-29 2013-04-17 サノフイ フェニル基を有するフェニル−［１，２，４］−オキサジアゾール−５−オン誘導体、その製造方法、及び医薬品としてのその使用

Also Published As

Publication number Publication date
US7709509B2 (en) 2010-05-04
US20080255212A1 (en) 2008-10-16
KR20060135857A (ko) 2006-12-29
AU2005231916A1 (en) 2005-10-20
MY142431A (en) 2010-11-30
AR050576A1 (es) 2006-11-08
ECSP066892A (es) 2006-11-24
PA8628701A1 (es) 2006-11-25
PE20060323A1 (es) 2006-03-31
UY28837A1 (es) 2005-10-31
HRP20090493T1 (hr) 2009-10-31
US20080262052A1 (en) 2008-10-23
US20070179191A1 (en) 2007-08-02
IL178056A0 (en) 2006-12-31
MA28495B1 (fr) 2007-03-01
DE602005015204D1 (de) 2009-08-13
BRPI0509517A (pt) 2007-09-11
SI1740583T1 (sl) 2009-12-31
ES2329484T3 (es) 2009-11-26
EP1586573A1 (en) 2005-10-19
JP2007530612A (ja) 2007-11-01
DOP2005000051A (es) 2005-12-15
SV2006002071A (es) 2006-01-30
NO20064981L (no) 2006-12-28
PL1740583T3 (pl) 2009-12-31
PT1740583E (pt) 2009-09-16
RS51186B (sr) 2010-10-31
TNSN06317A1 (en) 2007-12-03
CN100582104C (zh) 2010-01-20
TW200602342A (en) 2006-01-16
CA2561627A1 (en) 2005-10-20
WO2005097786A1 (en) 2005-10-20
HK1100408A1 (zh) 2007-09-21
CR8572A (es) 2007-12-04
DE602004004631D1 (de) 2007-03-22
CN1938300A (zh) 2007-03-28
ZA200606870B (en) 2008-04-30
EP1740583A1 (en) 2007-01-10
RU2006138498A (ru) 2008-05-10
EP1586573B1 (en) 2007-02-07
EP2083006A1 (en) 2009-07-29
RU2374243C2 (ru) 2009-11-27
CY1109370T1 (el) 2014-07-02
UA84203C2 (en) 2008-09-25
DK1740583T3 (da) 2009-10-19
EP1740583B1 (en) 2009-07-01
ATE435225T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
GT200500028A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos.
BRPI0606172A2 (pt) métodos e composições para o tratamento de distúrbios oculares
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CR20110509A (es) Composicion farmaceutica
CY1118902T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
GT200900175A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
UY30282A1 (es) Compuestos quimicos
UY31803A (es) Compuesto cristalino
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
NI201600160A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
NI201600161A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
GB2473579A (en) Stat3 and TYK2 as drug targets for neurodegenerative diseases
MX2014014066A (es) Compuestos de cromano.
UY29161A1 (es) Nuevos heterociclos
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6